On-Demand CME Videos
FC24: Palmoplantar Pustulosis: Looking Ahead to New Treatment Options: An Online Activity
About
Palmoplantar Pustulosis: Looking Ahead to New Treatment Options: An Online Activity
This activity is supported by an educational grant from Amgen.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 8, 2024
December 8, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Define the impact of palmoplantar pustulosis on patient quality of life (QoL)
Describe strategies for effectively diagnosing palmoplantar pustulosis
Review the latest clinical data pertaining to emerging therapeutics for palmoplantar pustulosis
Intended Audience
Faculty
Tina Bhutani, MD, MAS
CEO, Synergy Dermatology
Associate Clinical Professor of Dermatology
University of California, SF
San Francisco, CA
Joel Gelfand, MD, MSCE, FAAD
Penn Medicine
Director, Psoriasis and Phototherapy Treatment Center
Director, Center for Clinical Sciences in Dermatology
Philadelphia, Pennsylvania
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Advisory Board: Abbvie, Arcutis, Aslan, Boehringer-Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, Incyte, Janssen, Leo, Lilly, Pfizer, Novartis, Sanofi, SUN Pharma, Takeda, and UCB
Grant/Research Support: Amgen, Castle, CorEvitas, Novartis, Pfizer, and Regeneron
Speakers’ Bureau Honoraria: Amgen, Arcutis, Galderma, Janssen, Lilly and Leo
Ownership Interest (privately held): Owner of Synergy Dermatology
No relevant financial relationships with any Ineligible Company in the past 24 months.
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.